Prosight Management’s KalVista Pharmaceuticals KALV Stock Holding History

Prosight Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-240,000	Closed	-$1.89M	–	44
2023 Q1	$1.89M	Sell	240,000 -381,667	-61%	-$2.85M	0.89%	29
2022 Q4	$4.2M	Buy	621,667 +91,605	+17%	+$491K	2.29%	17
2022 Q3	$7.69M	Sell	530,062 -290,690	-35%	-$4.06M	4.12%	8
2022 Q2	$8.08M	Buy	820,752 +231,482	+39%	+$2.55M	6.36%	5
2022 Q1	$8.69M	Buy	589,270 +179,650	+44%	+$2.58M	5.61%	6
2021 Q4	$5.42M	Buy	409,620 +152,229	+59%	+$2.42M	3.24%	12
2021 Q3	$4.49M	Buy	257,391 +76,220	+42%	+$1.54M	2.47%	13
2021 Q2	$4.34M	Buy	+181,171	New	+$4.74M	2.71%	15

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management's KALV Position: Q2 2023 in Review

Prosight Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2023, closing a stake of 240,000 shares — an estimated $1.89M sold.

Prosight Management first reported a position in KALV in Q2 2021 and held it in 8 quarters. The position peaked at $8.69M in Q1 2022. 94 funds tracked by Wall St. Rank hold KALV as of Q2 2023.

Prosight Management reported no remaining KalVista Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Prosight Management sold 240,000 KalVista Pharmaceuticals shares in Q2 2023, an estimated $1.89M.
Prosight Management first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Prosight Management's KalVista Pharmaceuticals position peaked at $8.69M in Q1 2022.
94 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.